Newest studies

The evolving roles of imaging and fluid biomarkers for Alzheimer disease over the past quarter century

32/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: In 2004, the first radiotracer that bound amyloid plaques was reported, which enabled visualization of the amount and regional distribution of amyloid plaques in the brains of living individuals via positron emission tomography (PET). +4 more findings

• Biomarkers
• Brain Scans
• Brain Biology

Full summary, score breakdown and related studies → Original source

Development of small molecules promoting tau degradation in Alzheimer disease

32/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: Within around 700 new designed PROTACs, we found by computational modelling more than 25 PROTACs that were predicted to have a better ability to form ternary complexes than the previously reported PROTACs. +4 more findings

Full summary, score breakdown and related studies → Original source

Mosaic Loss of Chromosome Y and Plasma Aβ42/p‐tau181 Ratio as Biomarkers for Alzheimer's Disease in the Midwestern Amish

39/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: We observed two promising biomarkers of AD, mLOY and APR, both contribute discriminating AD and CI but differently. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

CSF YKL‐40 demonstrates stage‐specific effects of astrocytic reactivity on Alzheimer's Disease pathology

37/100 ✓ Peer-reviewed Tau biomarkers Alzheimer s & Dementia

Key finding: Both taus are very significantly correlated ( p 0,697 in all groups), and with YKL‐40 (r>0.430). +4 more findings

• Brain Biology
• Biomarkers

Full summary, score breakdown and related studies → Original source

Baseline Participant Characteristics in the DIAN‐TU‐001 Trial

47/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: As of a data cutoff of December 3, 2024, 243 participants were screened and 197 randomized in DIAN-TU-001 Tau NexGen trial (Cohort 1: 97; Cohort 2: 100). +4 more findings

• Clinical Trials
• Genetics

Full summary, score breakdown and related studies → Original source

Transcriptomic analysis from 3D cultures of Presilinin‐1 G206A carriers reveals genetic expression differences associated with age‐of‐onset variability

39/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: We sequenced a total of 38,577 nuclei and detected an average of 2,700 genes per cell. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Genetic Insights into Alzheimer's Disease from Cuban American Studies

38/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: This study replicated the associations of SORL1, CR1, ADAM17, RASGEF1C, SPI1 , and ADAMTS1 with AD risk and protection are found in Cuban Americans. +3 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Presenilin 2 regulates corticosterone-induced autophagic death of adult hippocampal neural stem cells

28/100 ✓ Peer-reviewed Risk genes beyond APOE Animal Cells and Systems

Key finding: We previously showed that chronic stress impairs adult hippocampal neurogenesis by triggering autophagic cell death of adult hippocampal neural stem (HCN) cells. +3 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Neurophysiological markers of cholinergic dysfunction in pre‐symptomatic autosomal dominant Alzheimer´s disease using Transcranial Magnetic Stimulation (TMS): research design and preliminary results

31/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: Here we present our research design and preliminary results in ADAD mutation carriers and controls. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease

33/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. +4 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease

33/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. +4 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

Low CSF APP refines diagnosis for p ‐tau negative Alzheimer‐like dementia

39/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: Concentrations of CSF APP were significantly lower in T- compared to T+ individuals across all clinical diagnostic groups across cohorts, regardless of A± status (Figure 1). +4 more findings

• Biomarkers
• Diagnosis
• Digital Tools

Full summary, score breakdown and related studies → Original source

Phenotypic Characterization of Recently Identified PSEN1 Genetic Variants in ADAD in Colombia

39/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: The sample included 61 participants (55.7% female), aged 18-58, with a median education of 12 years (IQR: 10-14). +4 more findings

• Genetics
• Early Stage

Full summary, score breakdown and related studies → Original source

Cryo‐EM structures of amyloid β filaments from cotton wool plaques in Alzheimer disease caused by the PSEN1 V261I and A431E mutations

31/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: CWPs consist predominantly of two novel arrangements of type I Aβ filaments, and we have designated them as type Ic and type Id Aβ filaments. +4 more findings

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

A Novel TREM2 Small Molecule Agonist MTX46943 Re‐Programs Human Microglia and Reduces Amyloid Pathology In Vivo

33/100 ✓ Peer-reviewed Risk genes beyond APOE Alzheimer s & Dementia

Key finding: MTX46943-mediated TREM2 activation leads to TREM2/DAP12 receptor complex formation and stabilizes surface location required for downstream signaling and microglia activation. +4 more findings

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

The Relationship Between Brain Structure and Neuropsychiatric Symptoms in Patients With Mild Cognitive Impairment and Alzheimer's Dementia

42/100 ✓ Peer-reviewed Mild cognitive impairment International Journal of Geriatric Psychiatry

Key finding: All volumes showed the smallest in dementia, the intermediate in MCI, and the largest in healthy controls. +4 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment

38/100 ✓ Peer-reviewed Mild cognitive impairment Alzheimer s & Dementia

Key finding: Compared to CN, we identified 32 differential metabolites in AD and 49 in MCI serum. +4 more findings

• Early Stage
• Diagnosis

Full summary, score breakdown and related studies → Original source

Alterations in gut microbiota and plasma metabolites: a multi-omics study of mild cognitive impairment in Parkinson’s disease

41/100 ✓ Peer-reviewed Mild cognitive impairment Frontiers in Neuroscience

Key finding: Our multi-omics study revealed distinct gut microbiota and metabolite alterations in PD patients with cognitive impairment, highlighting gut-brain axis dysfunction. +4 more findings

• Early Stage
• Other Dementias

Full summary, score breakdown and related studies → Original source

Time‐dependent biomarker accuracy in forecasting mild cognitive impairment

48/100 ✓ Peer-reviewed Mild cognitive impairment Alzheimer s & Dementia

Key finding: Neurophysiological activity features and tau pet provided additional information to the clinical model when acquired up to ∼4 years prior to diagnosis, but their accuracy decreased at larger intervals. +4 more findings

• Biomarkers
• Early Stage

Full summary, score breakdown and related studies → Original source

A Four‐Arm Randomized Controlled Trial on the Effects of Multi‐Dimensional Cognitive Intervention in Parkinson's Disease Patients with Mild Cognitive Impairment and Subjective Cognitive Decline (REMIND)

54/100 ✓ Peer-reviewed Mild cognitive impairment Alzheimer s & Dementia

Key finding: The primary outcome of this study will be the total score on the Montreal Cognitive Assessment (MOCA). +4 more findings

• Clinical Trials
• Early Stage
• Diagnosis

Full summary, score breakdown and related studies → Original source

Gray and white matter pathology progression in Parkinson's disease patients that develop mild cognitive impairment

49/100 ✓ Peer-reviewed Mild cognitive impairment Alzheimer s & Dementia

Key finding: All included PD patients were cognitively normal at baseline and had 6 years of follow-up assessments available for cognitive status. +4 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB)

53/100 ✓ Peer-reviewed Lewy body dementia Alzheimer s & Dementia

Key finding: Of 293 participants screened, 130 were randomized, and 109 (83.8%) completed the study. +4 more findings

• Other Dementias
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Molecular modeling to simulation: insights into Gaussian QSAR, molecular docking, and DFT for identification of HDAC3 inhibitors for neurocognitive vascular dementia

41/100 ✓ Peer-reviewed Lewy body dementia Scientific Reports

Key finding: The top two hits—57402 and 46381 represented interactions with zinc-binding and amino acids such as HIE172 and HIE135 GLY143, and ASP93 residues compared with RGFP966. +1 more finding

• Other Dementias

Full summary, score breakdown and related studies → Original source

Depression preceding and following the diagnosis of Parkinson’s disease and Lewy body dementia

50/100 ✓ Peer-reviewed Lewy body dementia General Psychiatry

Key finding: We identified 17 711 patients with PD or LBD. +4 more findings

• Other Dementias
• Diagnosis

Full summary, score breakdown and related studies → Original source

Functional capacity in Peruvian people with Alzheimer's disease and frontotemporal dementia

50/100 ✓ Peer-reviewed Lewy body dementia Alzheimer s & Dementia

Key finding: Functional impairment increased progressively from normal cognition to dementia. +4 more findings

• Other Dementias

Full summary, score breakdown and related studies → Original source